Poland· PL-100448832
Jemperli
A dostarlimab product containing dostarlimabum, registered in Poland by GlaxoSmithKline (Ireland) Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Dostarlimab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF07 (dostarlimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Dostarlimab · ATC L01FF07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Dostarlimabum
- Manufacturer
- GlaxoSmithKline (Ireland) Limited
- Country
- Poland (PL)
- ATC code
- L01FF07
- ATC class
- Dostarlimab
- Defined daily dose
- 24 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991449872
- gtin05054290001075
- gtin05054290000634
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dostarlimab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandJEMPERLIGlaxoSmithKline Trading Services Limited
- SpainJEMPERLI 500 mg CONCENTRADO PARA SOLUCION PARA PERFUSIONGlaxosmithkline Trading Services Limited
- SwitzerlandJemperli
- CzechiaJEMPERLIGlaxoSmithKline Trading Services Limited, Dublin
- FranceJEMPERLI 500 mg, solution à diluer pour perfusionGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- United KingdomJemperli 500mg/10ml concentrate for solution for infusion vialsGlaxoSmithKline UK Ltd
- IrelandJEMPERLI 500 mg concentrate for solution for infusionGlaxoSmithKline Trading Services Limited
- IcelandJemperliGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jemperli
- Liechtenstein · Jemperli
- Norway · Jemperli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b2c71535-6d46-498f-a22b-f785f0382c96 GET /v1/drugs/b2c71535-6d46-498f-a22b-f785f0382c96?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "50 mg/ml",
"packaging": "05909991449872 ¦ Rpz ¦ EU/1/21/1538/001 ¦ 139485\n1 fiol. 10 ml\n¦ UR/Z/4c/042/22 - 05054290001075 ¦ UR/Z/4c/183/22 - 05054290000634 ¦ UR/Z/4c/007/23 - 05054290000634 ¦ UR/Z/4c/161/22 - 05054290000634",
"substance": "Dostarlimabum 50 mg/ml",
"common_name": "Dostarlimabum",
"pl_product_id": "100448832",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about dostarlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.